The Twisted Pink Metastatic Breast Cancer Impact Award will provide funding to independently conduct basic, translational, and clinical research in metastatic breast cancer. The overall goal of this funding is to accelerate understanding and advancements in clinical applications for people living with metastatic breast cancer.
Breast cancer is the most common cancer in women in the United States and is the second most common cause of death from cancer in women. In 2023, an estimated 300,590 people (297,790 women and 2,800 men) in the United States will be diagnosed with invasive breast cancer. It is estimated that 43,700 people (43,170 women and 530 men) deaths from this disease will occur.
Metastatic breast cancer (mBC) is cancer that has spread (metastasized) to other organs in the body. Another name for metastatic breast cancer is advanced breast cancer or stage IV breast cancer. In the United States, 6% of women have metastatic breast cancer when they are first diagnosed. Metastatic breast cancer is not curable, but it is treatable. Twisted Pink’s mission is to provide hope and connection to people living with metastatic breast cancer by funding bold breakthroughs in research and awareness of the disease. The Twisted Pink Metastatic Breast Cancer Impact Award will support creative, unique and innovative research and is open to tenure-track faculty applicants at a non-profit academic, medical or research institution in the United States.
Funding Available
The grant will provide $200,000 in funding for the direct costs of the research over a 24-month project period. Indirect costs are not allowed. There is funding for one award. The grant agreement term is August 1, 2024 – July 31, 2026.
Conquer Cancer is the scientific partner for this grant and provides scientific expertise, peer review and grants administration. Twisted Pink is the sponsor of the research grant. The grant recipient must agree to be bound to the Terms and Conditions of Twisted Pink. Any publication associated with the research must recognize Twisted Pink as the sponsor.
Eligibility Criteria
Applicants must meet the following criteria:
- hold a Doctoral Degree (MD, PhD, MD/PhD, DO, or comparable degree)
- be in a tenure-track or equivalent faculty position at the time of application submission.
- be working at a non-profit academic, medical or research institution in the U.S.
- have a valid, active medical license in the U.S. at the time of application (if necessary for the conduct of the proposed research project)
- have demonstrated the ability to carry out investigator-initiated research focused on metastatic breast cancer; and,
- be able to commit sufficient time and effort to assure successful progress of the project during the award period.
The award does not require U.S. citizenship or permanent residency. However, the proposed research must be conducted in a non-profit academic, medical or research institution in the U.S. The institution is responsible for documenting the applicant’s legal eligibility to work in the U.S. for the entire duration of the award.
Multiple applications will be accepted from a single institution, provided that each application has a different applicant/Principal Investigator and represents a distinct hypothesis.
Conquer Cancer and the mBC Impact Award Grant Review Committee reserves the right to evaluate and determine an applicant’s eligibility based on the information and justifications included in the application materials. Applicants who are uncertain about their eligibility are encouraged to contact the Grants team for clarification and provide their CV for evaluation.
Application Instructions
The application must be submitted in accordance with the requirements and instructions of the Request for Proposals (RFP) by the application deadline. A Letter of Intent (LOI) is required. All application materials must be in English and must be submitted through the Application Portal. Paper applications or applications sent by e-mail or fax will not be accepted. If you have questions, please email the Grants team.
Key Dates
Letter of Intent Due: January 29, 2024, by 11:59 PM ET
Letter of Intent Notifications: LOIs will be approved on a rolling basis but no later than February 5, 2024
Full Applications Due: March 29, 2024, by 11:59 PM ET
Anticipated Notification Date: May 2024
Anticipated Award Term: August 1, 2024 – July 31, 2026
EveryGrant®
This grant is administered in collaboration with EveryGrant®, Conquer Cancer, the ASCO Foundation’s, end-to-end, white label solution. EveryGrant® helps organizations develop and deliver grants programs that attract the brightest researchers and make a difference for people with cancer everywhere.